Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Phase 2 Recruiting
92 enrolled
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Phase 2 Recruiting
15 enrolled
BRAZAN
Phase 2 Recruiting
60 enrolled
Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 Recruiting
45 enrolled
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
33 enrolled
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Phase 2 Recruiting
108 enrolled
GLOASIS
Phase 2 Recruiting
100 enrolled
FIL_MOZART
Phase 2 Recruiting
56 enrolled
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Phase 2 Recruiting
21 enrolled
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Phase 2 Recruiting
36 enrolled
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Phase 2 Recruiting
42 enrolled
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Phase 2 Recruiting
152 enrolled
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Phase 2 Recruiting
79 enrolled
ZEBRA
Phase 2 Recruiting
55 enrolled
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Phase 2 Recruiting
20 enrolled
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Phase 2 Recruiting
227 enrolled
BOSon
Phase 2 Recruiting
40 enrolled
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Phase 2 Recruiting
230 enrolled
Pola-ZR2P in Previously Untreated DLBCL
Phase 2 Recruiting
80 enrolled
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Phase 2 Recruiting
40 enrolled
ZEBRA
Phase 2 Recruiting
50 enrolled
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Recruiting
106 enrolled
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Phase 2 Recruiting
240 enrolled
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Phase 2 Recruiting
52 enrolled
ZBR
Phase 2 Recruiting
42 enrolled
ZGR
Phase 2 Recruiting
39 enrolled
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Phase 2 Recruiting
30 enrolled
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 2 Recruiting
23 enrolled
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Phase 2 Recruiting
41 enrolled